Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exosomes, Azelastine, and Interferon alpha-2b Nasal Spray for Chronic Rhinosinusitis
NCT07635459Phase 1Not yet recruiting
- Sponsor
- Xinxiang Medical University First Affiliated Hospital
- Start
- Jul 2026
- Primary completion
- Jun 2027
01
Overview
Phase 1, randomised, double-blind trial of umbilical cord derived mesenchymal stem cells exosomes in chronic rhinosinusitis (CRS) (3 arms), sponsored by Xinxiang Medical University First Affiliated Hospital. Primary endpoint: Number of Participants with Treatment-Related Adverse Events at Day 90. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
umbilical cord derived mesenchymal stem cells exosomes
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on NCT07635459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07635459.